Research Articles | Page 83 | Aplastic Anemia & MDS International Foundation Return to top.
  1. Articles
  2. Research Articles

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial Mar 2016 Lancet Oncol myelodysplastic syndromes (MDS)
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes Oct 2017 Blood Advances myelodysplastic syndromes (MDS)
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) Jan 2021 Cancer Causes & Control : CCC myelodysplastic syndromes (MDS)
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation Mar 2014 J Natl Cancer Inst myelodysplastic syndromes (MDS)
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients Feb 2013 Leukemia myelodysplastic syndromes (MDS)
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling? Feb 2014 Expert Rev Hematol myelodysplastic syndromes (MDS)
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Mar 2021 Cancers chronic myelomonocytic leukaemia (CMML), myelodysplastic syndromes (MDS)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Jun 2013 J Clin Oncol myelodysplastic syndromes (MDS)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy Jun 2017 Br J Haematol myelodysplastic syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Share with addtoany.com.